Cholangiocarcinoma: three different entities based on location
暂无分享,去创建一个
[1] J. Samra,et al. Resection margin influences survival after pancreatoduodenectomy for distal cholangiocarcinoma. , 2017, American journal of surgery.
[2] Steven C Cunningham,et al. Cholangiocarcinoma: Thirty-one-Year Experience With 564 Patients at a Single Institution , 2007, Annals of surgery.
[3] M. Nagino,et al. Hepatectomy With Portal Vein Resection for Hilar Cholangiocarcinoma: Audit of 52 Consecutive Cases , 2003, Annals of surgery.
[4] M. Choti,et al. Trends in Survival after Surgery for Cholangiocarcinoma: A 30-Year Population-Based SEER Database Analysis , 2007, Journal of Gastrointestinal Surgery.
[5] T. Pawlik,et al. Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. , 2014, JAMA surgery.
[6] P. Tushar,et al. Intrahepatic, perihilar and distal cholangiocarcinoma: Management and outcomes. , 2017, Annals of hepatology.
[7] J. Raftery,et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. , 2019, The Lancet. Oncology.
[8] Yajin Chen,et al. Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma? A systematic review and meta-analysis. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[9] J. Vauthey,et al. Recent Advances in the Management of Cholangiocarcinomas , 1994, Seminars in liver disease.
[10] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[11] A. D. De Rose,et al. Association of Lymph Node Status With Survival in Patients After Liver Resection for Hilar Cholangiocarcinoma in an Italian Multicenter Analysis. , 2016, JAMA surgery.
[12] T. Pawlik,et al. Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. , 2009, Surgery.
[13] G. Gores,et al. Cholangiocarcinoma — evolving concepts and therapeutic strategies , 2018, Nature Reviews Clinical Oncology.
[14] G. Spolverato,et al. Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme. , 2016, Journal of the American College of Surgeons.
[15] Jiahong Dong,et al. Influence of surgical margins on overall survival after resection of intrahepatic cholangiocarcinoma , 2016, Medicine.
[16] M. Nagino,et al. A Study on Radial Margin Status in Resected Perihilar Cholangiocarcinoma , 2019, Annals of surgery.
[17] G. Spolverato,et al. The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma , 2015, Annals of Surgical Oncology.
[18] Charles R. Thomas,et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Q. Xia,et al. Cholangiocarcinoma: anatomical location-dependent clinical, prognostic, and genetic disparities. , 2019, Annals of translational medicine.